Registration gives the benefit of site update e-mails and additional information from Takeda on new education materials and events.
ADHD Institute Register

Meeting of Minds XII

Reports covering key ADHD topics discussed at Meeting of Minds XII are available now

Read more

33rd European Clinical Neuropsychopharmacology (ECNP) Virtual Congress

A report covering key ADHD topics discussed at ECNP 2020 is available now.

Read more

28th European Congress of Psychiatry (EPA) Virtual Congress

A report covering key ADHD topics discussed at EPA 2020 is available now.

Read more

Psychiatric comorbidities

eLearning module: Psychiatric comorbidities


Launch now

Missed the Neurobiology of ADHD disorder webinar?

Watch the Webinar now, participate in the knowledge checks and hear the Q&A panel discussion

Watch now

An interactive guide to the MOA of selected medications used in the treatment of ADHD

This is an MOA of pharmacological treatments only. Pharmacological treatment is not indicated for all patients and it must be used as part of a multimodal treatment approach

Launch now

Guidelines – UPDATE

Clinical guidelines are available to provide evidence-based recommendations for the management of ADHD to help guide appropriate and rational choices of treatment

Read more

ADHD is a lifelong disorder

ADHD is a chronic neurodevelopmental disorder which can affect children, adolescents and adults

Read more

The neurobiology of ADHD
is highly complex

Evidence exists for the association between ADHD and possible structural, functional and neurotransmitter alterations in various regions of the brain in children, adolescents and adults with ADHD

Read more

Assessment and diagnosis

ADHD assessment involves clinical examination, interviews and rating scales. Formal ADHD diagnosis typically utilises DSM-5TM or ICD-10 classification systems

Read more

Optimal management of ADHD

The optimal management of ADHD process should always consider input from the patient, family/caregivers and school to help establish an appropriate and extensive treatment programme (non-pharmacological and pharmacological therapy), goals and assessment/follow-up, resulting in a tailored multimodal treatment plan centred on the patient

Read more

Attention-deficit hyperactivity disorder (ADHD) is a diverse condition characterised by symptoms of inattention, hyperactivity and impulsivity; and can have a significant impact on patients’ lives.1,2 This website provides educational resources intended for healthcare professionals outside the US with an interest in ADHD. It aims to share scientific advances in ADHD research and provide expert opinions and medical education to support the healthcare professional community.

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 2013.
  2. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Available at: Last updated 1993; 1: 1-263. Accessed February 2019.
Filter content by:

ADHD Institue logo

You’re now being transferred to

and are leaving the ADHD Institute site

Takeda has no influence or control over the content of this third party website.

Continue Cancel